Clinical Trials Browser

Phase 3 × INDUSTRY × Triple Negative Breast Neoplasms × Clear all

NCT06382142 2026-04-20

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT06841354 2026-04-20

TroFuse-011

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT06966700 2026-04-17

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07533123 2026-04-16

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT06393374 2026-04-13

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT05382299 2026-04-06

ASCENT-03

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT04251533 2026-04-03

EPIK-B3

Phase 3 Terminated

137 enrolled 21 charts

Triple Negative Breast Neoplasms

NCT06767527 2026-03-16

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT06279364 2026-01-27

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT06519370 2026-01-22

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT05633654 2026-01-20

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT04148911 2025-12-26

EL1SSAR

Phase 3 Completed

184 enrolled 15 charts

Triple Negative Breast Neoplasms

NCT03997123 2025-12-22

CAPItello-290

Phase 3 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07111832 2025-12-18

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT05347134 2025-12-09

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT03371017 2025-11-12

IMpassion132

Phase 3 Completed

595 enrolled 37 charts

Triple Negative Breast Neoplasms

NCT03036488 2025-10-29

MK-3475-522

Phase 3 Completed

1,174 enrolled 2 FDA

Triple Negative Breast Neoplasms

NCT06732323 2025-09-23

A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT05382286 2025-09-18

ASCENT-04

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT04915755 2025-07-16

ZEST

Phase 3 Active not recruiting

40 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03562637 2025-05-09

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT03671044 2025-03-21

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT06419621 2025-03-12

PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT02819518 2024-11-27

KEYNOTE-355

Phase 3 Completed

882 enrolled 41 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT03498716 2024-08-21

IMpassion030

Phase 3 Terminated

2,199 enrolled 13 charts

Triple Negative Breast Neoplasms

NCT04799249 2024-08-01

PRESERVE 2

Phase 3 Completed

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05134194 2024-04-16

A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer

Phase 3 Terminated

Triple Negative Breast Neoplasms

NCT04177108 2024-03-27

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Phase 3 Completed

242 enrolled 12 charts

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases, Triple Negative Breast Neoplasms

NCT04613674 2024-03-27

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 3 Completed

Triple Negative Breast Neoplasms

NCT03125902 2024-03-26

IMpassion131

Phase 3 Completed

653 enrolled 33 charts

Triple Negative Breast Neoplasms

NCT03197935 2023-10-26

IMpassion031

Phase 3 Completed

333 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT04335006 2023-05-06

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Phase 3 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03002103 2023-04-26

A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer

Phase 3 Suspended

Triple Negative Breast Neoplasms

NCT02425891 2022-07-19

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Phase 3 Completed

902 enrolled 27 charts 1 FDA

Triple Negative Breast Neoplasms

NCT02201381 2022-07-18

METRICS

Phase 3 Withdrawn

BreastCNSGastrointestinalGynecologic

Brain Neoplasms, Breast Neoplasms, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT02555657 2021-12-10

KEYNOTE-119

Phase 3 Completed

622 enrolled 26 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02032277 2021-01-20

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Phase 3 Completed

Neoplasms, Triple Negative Breast Neoplasms

NCT04405505 2020-05-28

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Phase 3 Unknown

Triple Negative Breast Neoplasms

NCT04301739 2020-03-12

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

Phase 3 Not yet recruiting

Triple Negative Breast Neoplasms

NCT03777579 2019-08-08

A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Phase 3 Suspended

Triple Negative Breast Neoplasms

NCT02225470 2018-08-28

Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Phase 3 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00938652 2013-09-19

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Phase 3 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms